Treatment of Chronic Myelogenous Leukemia by Blocking Cytokine Alterations Found in Normal Stem and Progenitor Cells

Leukemic cells disrupt normal patterns of blood cell formation, but little is understood about the mechanism. We investigated whether leukemic cells alter functions of normal hematopoietic stem and progenitor cells. Exposure to chronic myelogenous leukemia (CML) caused normal mouse hematopoietic progenitor cells to divide more readily, altered their differentiation, and reduced their reconstitution and self-renewal potential. Interestingly, the normal bystander cells acquired gene expression patterns resembling their malignant counterparts. Therefore, much of the leukemia signature is mediated by extrinsic factors. Indeed, IL-6 was responsible for most of these changes. Compatible results were obtained when human CML were cultured with normal human hematopoietic progenitor cells. Furthermore, neutralization of IL-6 prevented these changes and treated the disease. [Display omitted] •Leukemic cells alter neighboring non-transformed hematopoietic progenitor cells•Imprinting of the leukemia on the normal progenitor cell counterparts mimics CML•The pro-inflammatory cytokine IL-6 mediates these changes in normal hematopoiesis•Treatment eliminates the leukemia upon targeted therapy against the IL-6 cytokine Welner et al. investigated whether chronic myelogenous leukemia (CML) cells alter normal hematopoietic stem/progenitor cells (HSPCs) in addition to outcompeting them. They show that CML cells promote proliferation, alter differentiation, and reduce self-renewal capacity of neighboring normal HSPCs via IL-6.